drugset / Trial / NCT07707505

Intracavernosal Exosomes vs. Rectal Ozone for Post-RARP Erectile Dysfunction

NCT07707505

RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, randomized, controlled trial aims to evaluate and compare the therapeutic efficacy of intracavernosal urine-derived exosomes and systemic rectal ozone therapy in patients experiencing erectile dysfunction (ED) post-robotic-assisted radical prostatectomy (RARP). Patients will be randomized into two distinct intervention arms. The primary objective is to assess the functional recovery of the erectile tissue via the International Index of Erectile Function (IIEF-5) over a 6-month follow-up period. Secondary endpoints include penile hemodynamic alterations and overall health-related quality of life.

Timeline

Start
2026-08-01
Primary completion
2027-01-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral
Subject Urine-Derived Exosomes Other / unclassified 2 ml Intravenous

Indications

No indication recorded.